ImmunoCellular Therapeutics (OTCBB:IMUC) has been generating loads of media hype recently from its encouraging phase one study results for a unique type of brain cancer treatment.
The Los Angeles-based company's ICT-107 vaccine was featured on a TV segment on CBS New York's Channel 2 Newscast, titled "Vaccine Could Kill Brain Tumours Using Body's Own Immune System".
Indeed, the vaccine uses cancer stem cells to target multiple tumour-associated antigens, which generate an antibody response from the body's immune system.
In other words, white blood cells are primed in the lab to attach to markers present in brain tumours, and these cells are then injected back into the body, where they travel to the brain and attack tumour cells.
The vaccine is designed for the treatment of glioblastoma multiforme, which is an aggressive type of brain tumor. Typically, brain cancers are difficult to treat, as doctors cannot usually cut out the whole cancer, with some tumour cells left behind.
The TV news story, by CBS’ Dr. Max Gomez, called ICT-107 a "promising vaccine" for the treatment of brain cancer.
In the story, Dr. Joseph Landolfi, a clinical investigator at New Jersey Neuroscience Institute, noted that in the company's double-blind phase one trial, 80% of the patients showed a two-year overall survival rate. Forty-four percent also showed a progression-free survival rate. Even more, six of the 16 clinical patients are now disease-free.
The company is continuing to investigate the vaccine in its ongoing phase two study.
“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions herehttp://www.proactiveinvestors.com/pages/terms”
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites